Refractoriness to platelet transfusions in patients undergoing myeloablative conditioning with consecutive hematopoietic progenitor cell transplantation represents a major clinical problem especially in patients with immunization against frequent antigens. Platelet glycoprotein (GP) IV (=CD36) is expressed in nearly 100% of white Europeans, while 2 to 11 percent of Asian and sub-Sahara African individuals are negative.
1-3 CD36 deficiency appears not to be associated with clinical symptoms. Lack of CD36 can present as type I deficiency with neither platelets nor monocytes expressing CD36 and type II deficiency with only platelets lacking GPIV. 4 Antibodies to CD36 developing after isoimmunization in type I deficiency can lead to serious complications such as platelet transfusion refractoriness, post transfusion purpura or neonatal alloimmune thrombocytopenia. 5 Here the case of a patient from Oman admitted for HPC transplantation with an aggressive NonHodgkin's lymphoma and refractoriness to platelet transfusions caused by a GPIV isoantibody is reported.
A 36-year-old patient with diffuse large B-cell lymphoma and incomplete response to initial chemotherapy and platelet transfusions in Oman came to our medical center in Germany for autologous hematopoietic progenitor cell therapy. No immunization against platelet antigens was reported at that time. He received mobilization chemotherapy with the CD20 antibody rituximab (375 mg/m 2 on day 1) and ICE (ifosfamide 5000 mg/m 2 on day 3, carboplatin (area under the curve, 5; capped at 800 mg) on day 3 and etoposide 100 mg/m 2 on days 2-4) combination chemotherapy. During aplasia, his platelet count dropped to 9 per nl and did not increase after infusion of one pooled random-donor platelet concentrate and three random single-donor apheresis platelet concentrates. Platelet serology included a commercial ELISA assay (GTI-PAK; GTI, Brookfield, WI, USA) in two versions (PAKPLUS and PAK12) with purified antigen coated to the plate, the platelet suspension immunofluorescence assay, the monoclonal antibody immobilization of platelet antigen assay 6 and AbScreen HLA class I ELISA (Biotest, Dreieich, Germany). The patient's serum was positive with glycoprotein IV (GPIV) in the PAKPLUS assay but completely negative in the PAK12 assay, lacking the GPIV preparation. No HLA class I antibodies were detected. The patient's serum reacted in the platelet suspension immunofluorescence test with 7/7 platelet preparations from German donors exhibiting reactivities corresponding to an anti-CD36 control alloantiserum (FER, kindly provided by Ph. Bierling, Paris, France). GPIV deficiency was demonstrated by flow cytometry on both the patient's platelets and monocytes using the CD36 monoclonal antibody clone FA6.152 (Immunotech, Marseille, France), suggesting type I deficiency ( Figure 1 ). In addition, his platelets were negative with the CD36-specific serum FER in the platelet suspension immunofluorescence test and the CaptureP assay (Immucor, Ro¨dermark, Germany) in contrast to CD36-positive control platelets. Whereas FER produced positive results in the monoclonal antibody immobilization of platelet antigen assay, the patient's serum did not react with any of three monoclonal antibodies to CD36 (clone FA6.152 and clone 1A7, Dianova, Hamburg, Germany and clone 131.4 kindly provided by B Curtis, Milwaukee, WI, USA) in combination with CD36-positive platelets, which may be due to steric hindrance.
After mobilization chemotherapy, the patient's platelet count recovered spontaneously without further treatment, with a peak count of 147 per nl. Autologous hematopoietic progenitor cells were successfully harvested and 12.16 Â 10 6 CD34-positive cells per kg body weight were cryopreserved. During workup for high-dose chemotherapy and hematopoietic progenitor cell transplantation, a search for CD36-negative platelet donors in different internationally operating blood centers within Europe and the United States was unsuccessful. The Japanese Red Cross could have provided CD36-negative platelets, but the transportation time of 18-24 h could have affected viability and platelet function. No standardized and validated protocol for long-distance transportation was available. Harvest and consecutive cryopreservation of autologous platelets of the patient for platelet support at time of aplasia is neither an established nor a standardized method. Therefore, blood samples of six of the patient's relatives (two siblings, four nephews) living in Oman were shipped to our center for testing, and five proved to be GPIV-negative. The patient was not conditioned until two nephews traveled to Germany and, based on a negative platelet crossmatch, served as platelet donors. Conditioning was performed with R-BEAM (rituximab 375 mg/m 2 on days À8 and À2, carmustine 300 mg/m 2 on day À7, etoposide 200 mg/m 2 on days À6 to À3, cytosine arabinoside 400 mg/m 2 on days À6 to À3 and melphalan 140 mg/m 2 on day À2), and 12.16 Â 10 6 CD34-positive cells per kg of body weight were infused on day 0. Platelet count at that time was 56 per nl. From days þ 4 to þ 12 after transplantation, the patient suffered from infectious complications, with several fever episodes per day, although different intravenous antibiotics and voriconazole as anti-fungal medication were administered. In addition, the patient had severe mucositis, and needed parental nutrition and intravenous morphine. During this episode, the patient was transfused with nine platelet apheresis units over 10 days, donated by his two relatives to maintain a platelet count X10 per nl. The platelet count remained stable between 13 and 25 per nl on days þ 3 to þ 13 after transplantation without bleeding complications (Figure 2) . Although a classic 1-h post-platelet transfusion increment measurement was not available, a 5-h post-platelet transfusion increment, from 16 to 25 per nl and from 13 to 22 per nl, was documented twice during that time. Engraftment of white blood cells was observed on day þ 10 after transplant, and the platelet count recovered to 148 per nl on day þ 19 without further platelet support.
The molecular background of CD36 type I deficiency has been described for some individuals and ranged from single-nucleotide exchanges to absence of exons 1-3. 5, 7 In our patient, exons 1-14 could be amplified completely by PCR. Cloning (TA Cloning Kit with vector pCR2.1; Invitrogen, Paisley, UK) and sequencing (ABI 3730 XL; PE Applied Biosystems, Weiterstadt, Germany) of the 14 exons from genomic DNA showed no variation of the patient DNA compared to DNA of a GPIV-positive control donor and sequences from the National Center for Biotechnology Information databases. Therefore, variations of the genomic DNA cannot serve as an explanation for the GPIV type I deficiency in this patient and regulatory or transcriptional factors are more likely.
This case of CD36 deficiency in a patient with non-Hodgkin's lymphoma demonstrated that immunophenotyping may be a useful and rapid diagnostic tool when specific antisera or monoclonal antibodies are available.
Patients with an ethnic background different from the majority of blood donors from the respective region may cause major problems in blood product supply if they are immunized to blood groups with a nearly 100% prevalence. Searching for antigen-negative relatives can be successful, as demonstrated in this case. However, increasing migration and world-wide medical travel will make problems of blood supply more frequent. Strategies to manage these problems including recruitment of blood donors from ethnic minorities and establishment of standardized and reliable conditions of transportation for platelets over long distances from countries with a higher prevalence of CD36 deficiency are necessary. Furthermore, laboratory diagnosis of platelet antibodies must take into consideration the Letter to the Editor
